MX2016006993A - Procedimientos y composicion para la induccion de respuesta inmunitaria. - Google Patents

Procedimientos y composicion para la induccion de respuesta inmunitaria.

Info

Publication number
MX2016006993A
MX2016006993A MX2016006993A MX2016006993A MX2016006993A MX 2016006993 A MX2016006993 A MX 2016006993A MX 2016006993 A MX2016006993 A MX 2016006993A MX 2016006993 A MX2016006993 A MX 2016006993A MX 2016006993 A MX2016006993 A MX 2016006993A
Authority
MX
Mexico
Prior art keywords
induction
immune response
compositions
composition
bird
Prior art date
Application number
MX2016006993A
Other languages
English (en)
Inventor
Paul Joseph Dominowski
Sharath K Rai
Dennis L Foss
Mahan Suman
Mwangi Duncan
M Bricker Joseph
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016006993A publication Critical patent/MX2016006993A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona una composición sustancialmente libre de antígeno para la inducción a un mamífero o un ave de la respuesta inmunitaria innata en un ave o un mamífero, comprendiendo la composición una saponina, un esterol, una amina cuaternaria y un polímero poliacrílico; también se proporcionan procedimientos de uso de la composición.
MX2016006993A 2013-11-26 2014-11-21 Procedimientos y composicion para la induccion de respuesta inmunitaria. MX2016006993A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361909045P 2013-11-26 2013-11-26
PCT/US2014/066767 WO2015080959A1 (en) 2013-11-26 2014-11-21 Compositions for induction of immune response

Publications (1)

Publication Number Publication Date
MX2016006993A true MX2016006993A (es) 2017-01-09

Family

ID=52282855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006993A MX2016006993A (es) 2013-11-26 2014-11-21 Procedimientos y composicion para la induccion de respuesta inmunitaria.

Country Status (9)

Country Link
US (2) US11318200B2 (es)
EP (2) EP3074003B1 (es)
CN (2) CN105899199A (es)
AU (1) AU2014354967B2 (es)
BR (1) BR112016012127A2 (es)
CA (1) CA2932878C (es)
ES (1) ES2938847T3 (es)
MX (1) MX2016006993A (es)
WO (1) WO2015080959A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074003B1 (en) * 2013-11-26 2023-01-11 Zoetis Services LLC Compositions for induction of immune response
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132101B2 (en) 2002-02-27 2006-11-07 Duquesne University Of The Holy Ghost Compositions and methods for eliciting an immune response to gram-negative bacterial infections
US7828741B2 (en) 2002-12-20 2010-11-09 The Charlotte-Mecklenburg Hospital Authority Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
US20050244505A1 (en) 2003-12-11 2005-11-03 Higbee Russell G Immunotherapy compositions, method of making and method of use thereof
JP5393978B2 (ja) * 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
RS52930B (en) 2006-01-26 2014-02-28 Zoetis P Llc A NEW COMPOSITION OF GLYCOLIPID ADVANCE
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
DK2310046T3 (da) * 2008-06-27 2016-04-25 Zoetis Services Llc Hidtil ukendte adjuvanssammensætninger
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES
CN103561763A (zh) * 2011-02-04 2014-02-05 佐蒂斯有限责任公司 免疫原性支气管炎博德特氏菌组合物
US9623099B2 (en) * 2012-09-26 2017-04-18 Fvg Limited Subunit immersion vaccines for fish
CA3005608C (en) * 2013-09-19 2020-06-30 Zoetis Services Llc Water-in-oil emulsions comprising immunostimulatory oligonucleotides
CA2927224A1 (en) * 2013-10-17 2015-04-23 Zoetis Services Llc Methods and compositions for treatment of s. equi infection
EP3074003B1 (en) * 2013-11-26 2023-01-11 Zoetis Services LLC Compositions for induction of immune response
JP6854461B2 (ja) * 2014-11-05 2021-04-07 国立大学法人九州大学 ウイルスベクター、ｉＰＳ細胞の作製方法およびコンストラクト
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions

Also Published As

Publication number Publication date
CA2932878A1 (en) 2015-06-04
AU2014354967A1 (en) 2016-06-16
EP4241853A3 (en) 2023-11-22
US20180008701A1 (en) 2018-01-11
ES2938847T3 (es) 2023-04-17
CN105899199A (zh) 2016-08-24
EP4241853A2 (en) 2023-09-13
US20230100089A1 (en) 2023-03-30
BR112016012127A2 (pt) 2017-09-26
WO2015080959A1 (en) 2015-06-04
CN115154596A (zh) 2022-10-11
EP3074003A1 (en) 2016-10-05
AU2014354967B2 (en) 2019-04-11
EP3074003B1 (en) 2023-01-11
CA2932878C (en) 2020-11-03
US11318200B2 (en) 2022-05-03

Similar Documents

Publication Publication Date Title
HK1258041A1 (zh) 免疫細胞組合物和使用方法
PH12019500627A1 (en) Affinity-oligonucleotide conjugates and uses thereof
HK1245080A1 (zh) 自然殺傷細胞的方法和組合物
IL249011A0 (en) Methods and preparations related to exosomes
HK1253306A1 (zh) 抗ntb-a抗體及相關組合物和方法
EP2991646A4 (en) METHODS AND COMPOSITIONS FOR INCREASING CD4 + T LYMPHOCYTES REGULATORS
IL250818A0 (en) Methods and preparations for increasing immune responses
HK1226299A1 (zh) 用於誘發免疫反應的組合物、方法及工具
IL247614A0 (en) Methods and preparations for changing the immune response
EP2861719A4 (en) COMPOSITIONS AND METHODS FOR DECREASING AN IMMUNE RESPONSE
HK1250637A1 (zh) 用於引發免疫應答的劑和組合物
HK1206970A1 (en) Antigenic compositions and methods
HK1254514A1 (zh) 用於增强疫苗接種免疫反應的方法及組合物
IL245509A0 (en) Compositions and Methods Vectors Inducing Enhanced Immune Response Using Foxvirus Vectors
HK1246653A1 (zh) 奧那司酮延長釋放組合物和方法
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
HK1255052A1 (zh) 豬科動物物種中增强的免疫應答
MX2016006993A (es) Procedimientos y composicion para la induccion de respuesta inmunitaria.
IL244537A0 (en) New administration preparations and methods of their use
GB201620828D0 (en) Compositions of antibody construct-agonist conjugates and methods thereof
AU2015901218A0 (en) Agents and compositions for eliciting an immune response
AU2013901227A0 (en) Methods and compositions for inducing an immune response